Neurofibromatoses – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Neurofibromatoses – Drugs In Development, 2024 report and make more profitable business decisions.
Neurofibromatosis (NF) is a term for a group of genetic disorders that cause benign tumors to grow on nerve tissue. There are three types of NF: NF1, NF2, and schwannomatosis. Each type has different signs and symptoms, such as skin spots, freckles, bumps, hearing loss, vision loss, pain, and bone deformities. NF is caused by mutations in certain genes that regulate nerve cell growth and division. NF can be inherited from a parent or occur spontaneously during early development. NF affects the nervous system, including the brain, spinal cord, and peripheral nerves. NF has no cure, but treatments can help manage the symptoms and complications. Surgery, radiation therapy, chemotherapy, and medication are some of the options available. NF is one of the most common genetic diseases in the US, affecting about 1 in 3,000 people.
The Neurofibromatoses drugs in development market research report provide comprehensive information on the therapeutics under development for Neurofibromatoses, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neurofibromatoses and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Neurofibromatoses | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 33 molecules, with 31 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Neurofibromatoses therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Neurofibromatoses pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Neurofibromatoses treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Advenchen Laboratories LLCAlexion Pharmaceuticals Inc
AstraZeneca Plc
Astrogen Ltd
Betta Pharmaceuticals Co Ltd
Binjiang Pharma
Inc.
BioMed Valley Discoveries Inc
Bristol-Myers Squibb Co
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Cincinnati Children's Hospital Medical Center
Eli Lilly and Co
Fochon Pharmaceutical Ltd
Healx Ltd
Infixion Bioscience Inc
Millennium Pharmaceuticals Inc
Mulberry Biotherapeutics Inc
NFlection Therapeutics Inc
Novartis AG
OncoTherapy Science Inc
Pasithea Therapeutics Corp
Pfizer Inc
Plex Pharmaceuticals Inc
PRG S&Tech Inc
Recursion Pharmaceuticals Inc
Shanghai Sunway Biotech Co Ltd
Shouyao Holding Co Ltd
SpringWorks Therapeutics Inc
Therillume Inc
University of Alabama
Vyriad Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Neurofibromatoses reports